TNDM vs. GKOS, STVN, BLCO, INSP, NARI, PRCT, NVST, IRTC, NVCR, and LIVN
Should you be buying Tandem Diabetes Care stock or one of its competitors? The main competitors of Tandem Diabetes Care include Glaukos (GKOS), Stevanato Group (STVN), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Inari Medical (NARI), PROCEPT BioRobotics (PRCT), Envista (NVST), iRhythm Technologies (IRTC), NovoCure (NVCR), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.
Tandem Diabetes Care vs.
Glaukos (NYSE:GKOS) and Tandem Diabetes Care (NASDAQ:TNDM) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment.
In the previous week, Glaukos had 4 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 8 mentions for Glaukos and 4 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.12 beat Glaukos' score of 0.71 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.
Glaukos has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.
99.0% of Glaukos shares are owned by institutional investors. 6.4% of Glaukos shares are owned by insiders. Comparatively, 2.2% of Tandem Diabetes Care shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Tandem Diabetes Care has a net margin of -14.84% compared to Glaukos' net margin of -42.43%. Glaukos' return on equity of -18.99% beat Tandem Diabetes Care's return on equity.
Glaukos has higher earnings, but lower revenue than Tandem Diabetes Care. Glaukos is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.
Glaukos presently has a consensus target price of $147.75, indicating a potential downside of 5.65%. Tandem Diabetes Care has a consensus target price of $53.81, indicating a potential upside of 53.09%. Given Tandem Diabetes Care's higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than Glaukos.
Tandem Diabetes Care received 138 more outperform votes than Glaukos when rated by MarketBeat users. However, 64.83% of users gave Glaukos an outperform vote while only 61.28% of users gave Tandem Diabetes Care an outperform vote.
Summary
Glaukos beats Tandem Diabetes Care on 10 of the 19 factors compared between the two stocks.
Get Tandem Diabetes Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tandem Diabetes Care Competitors List
Related Companies and Tools
This page (NASDAQ:TNDM) was last updated on 1/20/2025 by MarketBeat.com Staff
